The Lupus Guidelines: Less Is Better

The data is reassuring. The safety profile is reassuring as well. And it's now open to start phase two trial and something that maybe we will look forward to in the next few years. So where was trial done? So trial was an multi-center of few countries. With a 9% placebo response. That's analysis. That's really, it's impressive. And that's a ticket to regulatory approval, if you ask me.